Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BDH IndustriesBOM:524828 +0.46%78 ROE % is 14.95% as of Mar. 2026, which is 2% below its 10-year median of 15.24. GuruFocus rates BOM:524828 with a GF Score™ of 78/100 and a GF Value™ of ₹391.10 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 938 Drug Manufacturers companies, BDH Industries ranks better than 78.36% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BDH Industries's annualized net income for the quarter that ended in Mar. 2026 was ₹115.2 Mil. BDH Industries's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹770.1 Mil. Therefore, BDH Industries's annualized ROE % for the quarter that ended in Mar. 2026 was 14.95%.
The historical rank and industry rank for BDH Industries's ROE % or its related term are showing as below:
BOM:524828'
s ROE % Range Over the Past 10 Years
Min: 11.8 Med: 15.24 Max: 16.89
Current: 14.99
During the past 13 years, BDH Industries's highest ROE % was 16.89%. The lowest was 11.80%. And the median was 15.24%.
BOM:524828's ROE % is ranked better than 78.36% of 938
companies
in the Drug Manufacturers industry
Industry Median: 5.955
vs BOM:524828: 14.99
BDH Industries (BOM:524828) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
BDH Industries ROE % Related Terms
BDH Industries ROE % Historical Data
* Premium members only.
The historical data trend for BDH Industries's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BDH Industries's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BDH Industries ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BDH Industries's ROE % distribution charts can be found below:
* The bar in red indicates where BDH Industries's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
BDH Industries (BOM:524828) has a ROE % of 14.95% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BDH Industries and its competitors. This is near median its historical median of 15.24. Over the past decade, BDH Industries' ROE % has ranged from 11.80 to 16.89. According to the industry distribution chart, BDH Industries ranks #203 out of 938 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is BDH Industries' ROE % too high?
BDH Industries' current ROE % of 14.95% is near median its 10-year median of 15.24. Over the past 10 years, this metric has ranged from a low of 11.80 to a high of 16.89. The Drug Manufacturers industry median ROE % is 5.96. BDH Industries' value of 14.95% is 151% above this industry median. Based on the distribution chart, BDH Industries ranks #203 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BDH Industries has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BDH Industries' ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BDH Industries ranks #203 out of 938 companies for ROE %. This places BDH Industries in the top 22% of its industry — outperforming the majority of peers. The industry median ROE % is 5.96. BDH Industries' value of 14.95% is 151% above this benchmark. Historically, BDH Industries' own ROE % has ranged from 11.80 to 16.89 over the past decade. While the company's 10-year median is 15.24 vs. the industry median of 5.96, BDH Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.96, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BDH Industries's current ROE % of 14.95% is 151% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BDH Industries and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BDH Industries's current ROE % is 14.95%, which is near median its own 10-year median of 15.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BDH Industries stock overvalued right now?
Based on GuruFocus' analysis, BDH Industries (BOM:524828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹391.10, compared to a current price of ₹581.35 — trading 48.6% above its estimated fair value. The current ROE % is 14.95%, which is near median its 10-year median of 15.24 and 151% above the Drug Manufacturers industry median of 5.96. BDH Industries' overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For BDH Industries (BOM:524828), the current ROE % is 14.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BDH Industries (BOM:524828) Overvalued in 2026?
Based on GuruFocus' analysis, BDH Industries stock appears to be overvalued.
The current stock price of ₹581.35 is trading 48.6% above its estimated GF Value™ of ₹391.10.
GuruFocus considers BDH Industries to be Significantly Overvalued.
Key valuation signals for BOM:524828:
ROE %: 14.95% (near median its 10-year median of 15.24)
GF Value™: ₹391.10 vs. price of ₹581.35 (48.6% above fair value)
Industry Position: 151% above the Drug Manufacturers median (#203 of 938)
No single metric tells the full story. See the BOM:524828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BDH Industries Ltd is an India based pharmaceutical company. It is engaged in the manufacturing of therapeutic formulations including various pharmaceuticals. The company has the following reportable segments; Pharmaceuticals and Renewable Energy. The majority of its revenue is generated from the Pharmaceuticals segment. The company's product portfolio encompasses therapeutic categories including antifungal, antibiotics, anticancer, antidiabetic, antidepressant, antiulcerant, antimalarials, anti-inflammatory, analgesic, antispasmodic, anti-tuberculosis, cardiovascular, dermatological, psychotropic, and others.
78GF Score
Get the complete analysis for BOM:524828
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524828 has been successfully added to your 
